Targeting ERβ, with a combination of natural estrogen-like compounds that bind the receptor with high selectivity, has been proposed as a therapeutic strategy for Leber’s hereditary optic neuropathy [139]. The gene discussed is ESR2; the disease is Leber hereditary optic neuropathy.